Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD(®) and VANTAFLU(®) in South Korean Subjects Aged ≥65 Years

BACKGROUD: Influenza vaccination is recommended for adults aged ≥65 years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study assessed the safety of the MF59-adjuvanted trivalent inactivated subunit influenza vaccine, which...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Infect Chemother
Main Authors: Yoo, Byung Wook, Kim, Chang Oh, Izu, Allen, Arora, Ashwani Kumar, Heijnen, Esther
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6312896/
https://ncbi.nlm.nih.gov/pubmed/30600653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3947/ic.2018.50.4.301
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados